8846威尼斯(中国百科)有限公司

临床模式苏州转化医学研究中心产品管线学术文献

Home - 研究开发 - 学术文献

学术文献

临床模式 
苏州转化医学研究中心 
产品管线 
学术文献 

GEMSTONE-302: Randomized, Double-Blind, Phase 3 Study of Sugemalimab or Placebo Plus Platinum-Based Chemotherapy as First-Line Treatment for Metastatic NSCLC

发表在：2021年世界肺癌大会 (WCLC)
Abstract 53 GEMSTONE-302: A Phase 3 Study of Platinum-Based Chemotherapy with Placebo or Sugemalimab, a PD-L1mAb, for metastatic NSCLC

发表在：2021年世界肺癌大会（WCLC)
Efficacy and Safety of Pralsetinib in Chinese Patients with Advanced RET Fusion+ Non-Small Cell Lung Cancer

发表在：2021年世界肺癌大会（WCLC)
Efficacy and Safety of Pralsetinib in Chinese Patients with Advanced RET Fusion+ Non-Small Cell Lung Cancer

发表在：2021年世界肺癌大会（WCLC)
CS5001, a novel ROR1 targeting antibody drug conjugate (ADC) armed with tumor cleavable β glucuronide linkers and pyrrolobenzodiazepine (PBD) prodrugs for hematological and solid malignancies

发表在：2021年第33届国际分子靶标与癌症治疗大会
Abstract LBA008: CS5001, a novel ROR1-targeting antibody drug conjugate (ADC) armed with tumor-cleavable β-glucuronide linkers and pyrrolobenzodiazepine (PBD) prodrugs for hematological and solid malignancies

发表在：2021年第33届国际分子靶标与癌症治疗大会
Preliminary safety and efficacy results from phase Ib study of the anti-CTLA-4 monoclonal antibody (mAb) CS1002 in combination with anti-PD-1 mAb CS1003 in patients with advanced solid tumors

发表在：发表在：2021年欧洲肿瘤内科学会（ESMO）年会
Preliminary safety and efficacy results from phase Ib study of the anti-CTLA-4 monoclonal antibody (mAb) CS1002 in combination with anti-PD-1 mAb CS1003 in patients with advanced solid tumors

发表在：2021年欧洲免疫肿瘤学大会(ESMO IO)

1 2 3 4 5 6 7

上一页4/12下一页

声明